Bizarre Patents
A Christmas stocking having illumination means associated therewith for signalling the arrival of Santa Claus.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| RE43298 | Peptides as NS3-serine protease inhibitors of hepatitis C virus The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of us... | 04/03/2012 |
| 7871621 | Anti-HBs monoclonal antibody An anti-HBs monoclonal antibody is described herein. This antibody can bind to the following: (i) a wild type HBsAg; (ii) at least one mutant HBsAg selected from the group consisting of a first mutant HBsAg and a second mutant HBsAg; and (iii) at least one mutant HB... | 01/18/2011 |
| 7785595 | Stabilized anti-hepatitis B (HBV) antibody formulations The present invention provides liquid formulations of antibodies or fragments thereof that specifically bind to a hepatitis B virus (HBV) antigen, which formulations exhibit stability, low to undetectable levels of aggregations, and very little to no loss of the bio... | 08/31/2010 |
| 7727529 | Human monoclonal antibody Fab fragments directed against HCV E2 glycoprotein and endowed with in vitro neutralizing activity The invention refers to a human antibody, or its functional fragments, directed against the HCV E2 glycoprotein, able to have a neutralizing activity in vivo; a composition for anti-HCV therapy comprising in a therapeutically effective amount the antibody; a composi... | 06/01/2010 |
| RE40831 | Human monoclonal antibodies to the hepatitis B surface antigen Disclosed is a process for obtaining hybridoma cell lines which produce human antibodies capable of binding to the hepatitis B virus surface antigen (HBVsAg), as well as the hybridoma cell lines, and antibodies produced by the cell lines. Also disclosed are various ... | 07/07/2009 |
| 7507408 | Anti hepatitis C virus antibody and uses thereof Described are novel antibodies specifically recognizing conformation dependent epitopes of HCV glycoprotein E2 and that are capable aof neutralizing the binding of E2 protein onto susceptible cells. Furthermore, antigens and epitopes recognized by the above-describe... | 03/24/2009 |
| 7371378 | Modified human IGF-IR antibodies The present invention relates to antibodies, which are directed to the human IGF-1 receptor (IGF-1R) and are to be administered for the treatment of cancer. The antibodies of the present invention have been altered to comprise antibodies with one or more selected ge... | 05/13/2008 |
| 7314919 | Human recombinant antibody against the hepatitis C (HCV) non structural NS3 protein nucleic acid and uses thereof An human antibody anti-NS3 protein of the hepatitis C virus (HCV) is described, as will as synthetic and recombinant fragments thereof able to inhibit the helicase activity of the NS3 protein, both in vitro and in vivo, and uses thereof. ... | 01/01/2008 |
| 7250166 | Human monoclonal antibodies that bind hepatitis C virus (HCV) E1 The present invention relates to materials and methods for treatment of hepatitis C. More closely, the invention relates to human monoclonal antibodies against HCV E1 antigen, to a reagent comprising such antibodies, and to vaccine compositions comprising such antib... | 07/31/2007 |
| 7241445 | Human monoclonal antibody against hepatitis C virus E2 glycoprotein Disclosed is a hybridoma cell line which produces human antibodies capable of binding to the hepatitis C virus (HCV) E2 glycoprotein and capable of neutralizing HCV infection in vivo in an animal model, as well as antibodies produced by the cell line. Also disclosed... | 07/10/2007 |
| 7226429 | Method for removal of viruses from blood by lectin affinity hemodialysis The present invention relates to a method for using lectins that bind to pathogens having high mannose surface glycoproteins or fragments thereof which contain high mannose glycoproteins, to remove them from infected blood or plasma in an extracorporeal setting. Acc... | 06/05/2007 |
| RE39586 | Human monoclonal antibody against Hepatitis B virus surface antigen (HBVSAG) Disclosed is a hybridoma cell line which produces human antibodies capable of binding to the hepatitis B virus surface antigen (HBVsAg), as well as antibodies produced by the cell line. Also disclosed are various uses of said antibodies in the prevention and treatme... | 04/24/2007 |
| 7195765 | Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents The present invention relates to a polynucleic acid composition comprising or consisting of at least one polynucleic acid containing 8 or more contiguous nucleotides corresponding to a nucleotide sequence from the region spanning positions 417 to 957 of the Core/E1 ... | 03/27/2007 |
| 7147852 | Methods for reducing TGF-β production and for promoting repair of liver damage Materials and methods for reducing TGF-β production and promoting repair of liver damage in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of an anti-zvegf3 antibody in combination ... | 12/12/2006 |
| 7112664 | Variable region of the monoclonal antibody against the HBV S-surface antigen and a gene encoding the same The present invention relates to a variable region of the monoclonal antibody against the S-surface antigen of hepatis B virus and a gene encoding the same, a recombinant vector containing the said gene, and a transformant obtained from the said recombinant vector. | 09/26/2006 |
| 7105303 | Antibodies to hepatitis C virus asialoglycoproteins Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more simi... | 09/12/2006 |
| 7101551 | Remedies for hepatitis C The present invention provides a substance which inhibits the binding between E2/NS1 protein of hepatitis C virus and a cell infectious with hepatitis C virus, a cell expressing CD81, or CD81. The present invention can provide a novel medicament which has an anti-vi... | 09/05/2006 |
| 7052830 | Hepatitis C virus peptides and uses thereof Novel hepatitis C virus (HCV) polypetides are provided which are not encoded by the standard HCV open reading frame. These alternate reading frame polypeptides are useful, inter alia, in vaccine compositions, in diagnosing HCV infection, and as therapeutic targets. | 05/30/2006 |
| 7026457 | Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use The present invention relates to a method for purifying recombinant HCV single or specific oligomeric envelope proteins selected from the group consisting of E1 and/or E1/E2 characterized in that upon lysing the transformed host cells to isolate the recombinantly ex... | 04/11/2006 |
| 6951646 | Anti hepatitis C virus antibody and uses thereof Described are novel antibodies specifically recognizing conformation dependent epitopes of HCV glycoprotein E2 and that are capable aof neutralizing the binding of E2 protein onto susceptible cells. Furthermore, antigens and epitopes recognized by the above-describe... | 10/04/2005 |
| 6930176 | Major neutralization site of hepatitis E virus and use of this neutralization site in methods of vaccination and in methods of screening for neutralizing antibodies to hepatitis E virus The invention describes the identification of major neutralization site of hepatitis E virus (HEV) and the use of this neutralization site in methods of vaccination and in methods of screening for neutralizing antibodies to HEV. The invention also describes the isol... | 08/16/2005 |
| 6924362 | Monoclonal antibodies specific for the E2 glycoprotein of hepatitic C virus and their use in the diagnosis, treatment, and prevention of hepatitis C The present invention describes the identification and characterization of five human HC E1-specific monoclonal antibodies isolated from a phage display library and their use in the diagnosis, treatment, and prevention of HCV in mammals, preferably humans. ... | 08/02/2005 |
| 6884417 | Monoclonal antibodies immunoreactive with lipopolysaccharide binding protein (LBP) and methods of their use The present invention concerns a method of treating LBP-mediated LPS-induced myeloid cell activation comprising administering a therapeutically effective amount of an anti-LBP monoclonal antibody molecule. A therapeutic composition comprising anti-LBP antibody molec... | 04/26/2005 |
| 6747136 | Human monoclonal antibodies specific for hepatitis C virus (HCV) E2 antigen The present invention relates to compositions derived from immunoglobulin molecules specific for the hepatitis C virus (HCV). More particularly, the invention is related to molecules which are capable of specifically binding with HCV E2 antigen. The molecules are us... | 06/08/2004 |
| 6685931 | Treatment of hepatitis C virus infections with interleukin-10 The hepatoprotective effect of IL-10 is described, in particular, the use of interleukin-10 in the treatment of liver damage (e.g. fibrosis or cirrhosis) in a difficult-to-treat patient afflicted with chronic hepatitis C virus infection who has failed to ... | 02/03/2004 |
| 6680053 | Variable region of the monoclonal antibody against the HBV S-surface antigen and a gene encoding the same The present invention relates to a variable region of the monoclonal antibody against the S-surface antigen of hepatis B virus and a gene encoding the same, a recombinant vector containing the said gene, and a transformant obtained from the said recombina... | 01/20/2004 |
| 6610295 | Processes for the production of HCMV glycoproteins, antibodies thereto and HCMV vaccines, and recombinant vectors therefor HCMV glycoproteins B and H have been identified. The gB protein is encoded by DNA in the HindIII F fragment of the HCMV genome lying between 1378 and 4095 bases from the F/D boundary. The gH protein is encoded by DNA in the HindIII L fragment lying betwee... | 08/26/2003 |
| 6565849 | Methods of enhancing activity of vaccines and vaccine compositions Disclosed are methods for vaccine priming, using co-treatment, at a temporally similar or at a previous time, with a priming antibody capable of priming, or enhancing, or potentiating the effects of a vaccine, or vaccine composition. Also disclosed are me... | 05/20/2003 |
| 6538114 | Human monoclonal antibodies specific for hepatitis C virus (HCV) E2 antigen The present invention relates to compositions derived from immunoglobulin molecules specific for the hepatitis C virus (HCV). More particularly, the invention is related to molecules which are capable of specifically binding with HCV E2 antigen. The molec... | 03/25/2003 |
| 6472159 | Use of an amphipathic compound for providing an adjuvant to a subunit vaccine The present invention provides a method of inducing an immune response to a subunit antigen in a non-responding subject by administering to the subject a composition comprising the subunit antigen and an amphipathic compound. A preferred antigen is a hepa... | 10/29/2002 |
| 6254867 | Human monoclonal antibodies to the hepatitis B surface antigen Disclosed is a process for obtaining hybridoma cell lines which produce human antibodies capable of binding to the hepatitis B virus surface antigen (HBVsAg), as well as the hybridoma cell lines, and antibodies produced by the cell lines. Also disclosed a... | 07/03/2001 |
| 6146629 | Human monoclonal antibody against Hepatitis B virus surface antigen (HBVsAg) Disclosed is a hybridoma cell line which produces human antibodies capable of binding to the hepatitis B virus surface antigen (HBVsAg), as well as antibodies produced by the cell line. Also disclosed are various uses of said antibodies in the prevention ... | 11/14/2000 |
| 6030616 | Hepatitis B escape mutant specific binding molecules Molecules which are capable of specifically binding to a hepatitis B escape mutant antigenic determinant include monoclonal antibodies secreted by the cell line SMH HBs 145/G/R/I (ECACC 92122312). SMH HBs 145/R/I (ECACC 93052626). SMH HBs 145/G/II (ECACC ... | 02/29/2000 |
| 5972347 | Pharmaceutical composition containing a neutralized virus and use thereof The invention relates to a pharmaceutical composition for prophylactic and/or therapeutic treatment of patients for immunization against a virus infection and is characterized in that this is obtainable by neutralizing the enriched and/or purified virus w... | 10/26/1999 |
| 5744135 | Method of raising an immune response with an anti-idiotypic antibody having correspondence with human hepatitis B surface antigen The invention comprises an anti-idiotypic antibody designated 2F10 and permitted variants thereof, which have antigenic properties similar to the group specific "a" determinant of human hepatitis B surface antigen HBsAg and have at least partial but not c... | 04/28/1998 |
| 5681695 | Method for increasing specificity in competitive immunoassays The invention is an improved immunoassay and method for detection of antibody to hepatitis B core antigen (anti-HBc). The improved assay comprises the addition of a reducing agent to decrease the number of false positive reactions in the assay.... | 10/28/1997 |
| 5648077 | Treatment of patients infected with hepatitis B virus with a human monoclonal antibody Monoclonal antibodies effective for the diagnosis and treatment of hepatitis B have been prepared from a cell line obtained by fusing a xenogeneic hybridoma designated SPAZ 4 with blood cells of a patient immunized with hepatitis B vaccine. The chimeric h... | 07/15/1997 |
| 5565354 | Production of human monoclonal antibodies specific for hepatitis B surface antigen Monoclonal antibodies effective for the diagnosis and treatment of diseases caused by infection with hepatitis B have been prepared from a cell line obtained by fusing a xenogeneic hybridoma designated SPAZ 4 with blood cells of a patient immunized with h... | 10/15/1996 |
| 5531989 | Immunoglobulin and fiber-containing composition for human gastrointestinal health A composition for restoring and maintaining gastrointestinal health comprises 40-60% by weight of an immunoglobulin composition comprising concentrated immunologically active immunoglobulins and 40-60% by weight of soluble dietary fiber selected from inul... | 07/02/1996 |
| 5531990 | Method of raising an immune response with an anti-idiotypic antibody having correspondence with human hepatitis B surface antigen The invention comprises an anti-idiotypic antibody designated 2F10 and permitted variants thereof, which have antigenic properties similar to the group specific "a" determinant of human hepatitis B surface antigen HBsAg and have at least partial but not c... | 07/02/1996 |
